Driving assessment in preclinical Alzheimer’s disease: progress to date and the path forward

BACKGROUND: Changes in driving behaviour may start at the preclinical stage of Alzheimer’s disease (AD), where the underlying AD biological process has begun in the presence of cognitive normality. Here, we summarize the emerging evidence suggesting that preclinical AD may impact everyday driving be...

Descripción completa

Detalles Bibliográficos
Autores principales: Bayat, Sayeh, Roe, Catherine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Mini Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641948/
https://www.ncbi.nlm.nih.gov/pubmed/36348410
http://dx.doi.org/10.1186/s13195-022-01109-1
_version_ 1784826198650519552
author Bayat, Sayeh
Roe, Catherine M.
author_facet Bayat, Sayeh
Roe, Catherine M.
author_sort Bayat, Sayeh
collection PubMed
description BACKGROUND: Changes in driving behaviour may start at the preclinical stage of Alzheimer’s disease (AD), where the underlying AD biological process has begun in the presence of cognitive normality. Here, we summarize the emerging evidence suggesting that preclinical AD may impact everyday driving behaviour. MAIN: Increasing evidence links driving performance and behaviour with AD biomarkers in cognitively intact older adults. These studies have found subtle yet detectable differences in driving associated with AD biomarker status among cognitively intact older adults. CONCLUSION: Recent studies suggest that changes in driving, a highly complex activity, are linked to, and can indicate the presence of, neuropathological AD. Future research must now examine the internal and external validity of driving for widespread use in identifying biological AD.
format Online
Article
Text
id pubmed-9641948
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96419482022-11-15 Driving assessment in preclinical Alzheimer’s disease: progress to date and the path forward Bayat, Sayeh Roe, Catherine M. Alzheimers Res Ther Mini Review BACKGROUND: Changes in driving behaviour may start at the preclinical stage of Alzheimer’s disease (AD), where the underlying AD biological process has begun in the presence of cognitive normality. Here, we summarize the emerging evidence suggesting that preclinical AD may impact everyday driving behaviour. MAIN: Increasing evidence links driving performance and behaviour with AD biomarkers in cognitively intact older adults. These studies have found subtle yet detectable differences in driving associated with AD biomarker status among cognitively intact older adults. CONCLUSION: Recent studies suggest that changes in driving, a highly complex activity, are linked to, and can indicate the presence of, neuropathological AD. Future research must now examine the internal and external validity of driving for widespread use in identifying biological AD. BioMed Central 2022-11-08 /pmc/articles/PMC9641948/ /pubmed/36348410 http://dx.doi.org/10.1186/s13195-022-01109-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Mini Review
Bayat, Sayeh
Roe, Catherine M.
Driving assessment in preclinical Alzheimer’s disease: progress to date and the path forward
title Driving assessment in preclinical Alzheimer’s disease: progress to date and the path forward
title_full Driving assessment in preclinical Alzheimer’s disease: progress to date and the path forward
title_fullStr Driving assessment in preclinical Alzheimer’s disease: progress to date and the path forward
title_full_unstemmed Driving assessment in preclinical Alzheimer’s disease: progress to date and the path forward
title_short Driving assessment in preclinical Alzheimer’s disease: progress to date and the path forward
title_sort driving assessment in preclinical alzheimer’s disease: progress to date and the path forward
topic Mini Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641948/
https://www.ncbi.nlm.nih.gov/pubmed/36348410
http://dx.doi.org/10.1186/s13195-022-01109-1
work_keys_str_mv AT bayatsayeh drivingassessmentinpreclinicalalzheimersdiseaseprogresstodateandthepathforward
AT roecatherinem drivingassessmentinpreclinicalalzheimersdiseaseprogresstodateandthepathforward

Ejemplares similares